French Matthew H, Faxon David P
Section of Cardiology, University of Chicago, Chicago, IL, USA.
Rev Cardiovasc Med. 2002 Fall;3(4):176-82.
Anticoagulation during percutaneous coronary intervention is critical to prevent abrupt and subacute closure. Although heparin has been the primary anticoagulant used for this purpose, a number of new drugs are now available. Low molecular weight heparin (LMWH) offers some advantages over unfractionated heparin, and clinical trials have shown its superiority. However, the longer half-life and lack of monitoring of LMWH make its use more difficult. The direct thrombin inhibitors also have been shown to have advantages in the treatment of patients with heparin-induced thrombocytopenia.
经皮冠状动脉介入治疗期间的抗凝对于预防急性和亚急性血管闭塞至关重要。尽管肝素一直是用于此目的的主要抗凝剂，但现在有许多新药可供使用。低分子量肝素（LMWH）相对于普通肝素具有一些优势，临床试验已证明其优越性。然而，LMWH较长的半衰期和缺乏监测使其使用更加困难。直接凝血酶抑制剂在治疗肝素诱导的血小板减少症患者方面也已显示出优势。
